

Liquid chromatography-tandem mass spectrometric assay for the quantification of CDK4/6 inhibitors in human plasma in a clinical context of drug-drug interaction

Fanny Leenhardt, Matthieu Gracia, Catherine Perrin, Claudia Muracciole-Bich, Bénédicte Marion, Céline Roques, Marie Alexandre, Nelly Firmin, Stephane Pouderoux, Litaty Mbatchi, et al.

▶ To cite this version:

Fanny Leenhardt, Matthieu Gracia, Catherine Perrin, Claudia Muracciole-Bich, Bénédicte Marion, et al.. Liquid chromatography–tandem mass spectrometric assay for the quantification of CDK4/6 inhibitors in human plasma in a clinical context of drug-drug interaction. Journal of Pharmaceutical and Biomedical Analysis, 2020, 188, pp.113438. 10.1016/j.jpba.2020.113438 . hal-03003807

HAL Id: hal-03003807 https://hal.science/hal-03003807

Submitted on 4 Jan 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1	Liquid chromatography-tandem mass spectrometric assay for the quantification of CDK4/6				
2	inhibitors in human plasma in a clinical context of drug-drug interaction.				
3					
4	Au	thors:			
5	Fanny Leenhardt ^{1,2,3} , Matthieu Gracia ^{1,3} , Catherine Perrin ⁴ , Claudia Muracciole-Bich ⁴ ,				
6	Bénédicte Marion ⁴ , Celine Roques ⁴ , Marie Alexandre ⁵ , Nelly Firmin ^{3,5} , Stephane Pouderoux ⁵				
7	Litaty Mbatchi ^{1,3,6} , Celine Gongora ³ , William Jacot ^{3,5} , Alexandre Evrard ^{1,3,6} .				
8					
9	1-	Laboratoire de Pharmacocinétique, Université de Montpellier, Faculté de Pharmacie,			
10		France			
11	2-	Service Pharmacie, Institut du Cancer de Montpellier, Université de Montpellier, 208 rue			
12		des Apothicaires, 34298, Montpellier, France.			
13	3-	Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Université			
14		de Montpellier, Montpellier, France.			
15	4-	Institut des Biomolécules Max Mousseron (IBMM), UMR 5247-CNRS-UM-ENSCM,			
16		Montpellier, France.			
17	5-	Département d'oncologie médicale, Institut du Cancer de Montpellier, Université de			
18		Montpellier, 208 rue des Apothicaires, 34298, Montpellier, France			
19	6-	Laboratoire de Biochimie et Biologie moléculaire, Centre Hospitalier Universitaire Nîmes,			
20		France			
21					
22	Co	rresponding author: Fanny Leenhardt, <u>fanny.leenhardt@icm.unicancer.fr</u> , Institut du			
23	cancer de Montpellier, 208 avenue des Apothicaires, Montpellier, France. Phone number :				
24	00 336 83 44 04 06				
25					
26					
27	Cre	edit authorship contribution statement:			
28	Fanny Leenhardt : Conceptualization, Methodology, Investigation, Formal analysis, Writing -				
29	Original Draft, Supervision, Funding acquisition				
30	Matthieu Gracia : Methodology, Investigation, Formal analysis, Writing - Original Draft				

- 31 Catherine Perrin : Methodology, Validation, Formal analysis, Writing Original Draft,
- 32 Supervision Claudia Muracciole-Bich : Methodology, Resources, Writing Original Draft
- 33 Bénédicte Marion : Methodology, Investigation, Resources
- 34 Celine Roques : Methodology, Investigation, Resources
- 35 Marie Alexandre : Investigation, Writing Original Draft
- 36 Nelly Firmin : Investigation, Writing Original Draft
- 37 Stephane Pouderoux : Investigation
- 38 Litaty Mbatchi : Writing Original Draft
- 39 Celine Gongora : Writing Original Draft, Project administration
- 40 William Jacot : Conceptualization, Investigation, Writing Original Draft, Supervision, Project
- 41 administration, Funding acquisition
- 42 Alexandre Evrard : Conceptualization, Methodology, Writing Original Draft, Supervision,
- 43 Project administration, Funding acquisition
- 44
- 45

46 Abstract

47

48 The CDK4/6 inhibitors palbociclib and ribociclib are kinase inhibitors used in association with 49 hormonal therapy for the management of patients with metastatic breast cancer. Like most 50 kinase inhibitors, therapeutic drug monitoring may be used for personalize their dosage. To this aim, we developed and validated a sensitive and specific HPLC-MS/MS method for 51 52 palbociclib and ribociclib quantification in blood samples. We then quantified exposure to 53 palbociclib (plasma trough concentration; C_{trough}) in a real-life cohort of patients with locally invasive or metastatic breast cancer (n=18) at day 15 of the first cycle of palbociclib 54 treatment to characterize palbociclib concentration at steady state (Clinicaltrials.gov 55 identifier NCT04025541). The geometric mean (± standard deviation [min-max]) of 56 57 palbociclib plasma C_{trough} was 88.58 ng/ml (± 26.4 [46.5 ng/mL – 133 ng/mL]) at day 15. Some covariates, such as drug-drug interactions, could explain the concentration variations 58

59	observed in our Caucasian cohort. These first results in real-life settings obtained with our
60	HPLC-MS/MS method give important information on palbociclib monitoring and
61	pharmacokinetic variability.
62	
63	Keywords: CDK4/6 inhibitor; HPLC-MS/MS; metastatic breast cancer; therapeutic drug
64	monitoring; drug-drug interactions
65	
66	

69

1. Introduction

70 The cyclin-dependent kinase 4/6 (CDK4/6) inhibitors palbociclib and ribociclib in combination with endocrine therapy are gradually becoming the first-line treatment for patients with 71 72 locally advanced or metastatic hormone receptor-positive (HR+) /HER2-negative breast cancer. However, these combination therapies show specific adverse events, such as severe 73 neutropenia (grade 3-4 for about 50% of patients), anemia, asthenia and liver toxicity [1]. 74 75 Nevertheless, their safety profile is globally good, and the febrile neutropenia incidence is about 1% in the pivotal clinical trials. Moreover, they have shown a clear benefit in terms of 76 progression-free survival compared with endocrine therapy alone [1]. As palbociclib and 77 ribociclib require only a single, fixed oral dose per day, their administration is easy to 78 manage but requires good patient's compliance for optimal drug exposure and therapeutic 79 80 effect. However, neutropenia often leads to treatment interruption/delay or dosage 81 modification, possibly linked to the lack of baseline dose adaptation in function, for instance, of age or body weight. In addition, targeted oral anti-cancer treatments, including CDK4/6 82 inhibitors, can display intra- and inter-individual pharmacokinetic variability that can 83 influence their efficacy and tolerance. Drug-drug interactions (DDI), food intake and genetic 84 85 polymorphisms in drug metabolizing enzymes are among the many factors that can influence drug-exposure variability. For instance, the observed variability concerning the 86 Area Under the plasma concentration Curve (AUC) and the steady state trough 87 concentration (C_{trough}) of tyrosine kinase inhibitors are about 32% for imatinib, 34% for 88 sunitinib, 24% for pazopanib, and 28% for vemurafenib [2]. For drugs with a linear 89 90 pharmacokinetics, efficacy and tolerance are mostly related to plasma exposure. Therefore, 91 therapeutic drug monitoring (TDM) is a useful tool to monitor this parameter. Practical

92 recommendations on TDM use are based on pharmacokinetic data, availability of analytical techniques, and clinical trials that used TDM for dosage adjustments [3]. TDM data and 93 recommendations are available for some oral targeted therapies used in solid tumors, such 94 as sunitinib in renal carcinoma and imatinib in gastrointestinal stromal tumor and leukemia 95 chronic myeloid [4]. Conversely, very few evidence-based data are available on TDM 96 97 usefulness for oral targeted therapies used in breast cancer, such as everolimus and lapatinib. Some methods have been validated for the plasma quantification of CDK4/6 98 99 inhibitors, but they are less used in real-life settings [5-7]. Therefore, we developed a specific high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) 100 method suitable for TDM of palbociclib and ribociclib in real-life settings. Here, we report the 101 102 method validation and also preliminary results obtained in 18 patients with breast cancer at 103 day 15 of the first cycle of palbociclib treatment.

104 **2. Material, patients and methods**

105 2.1. Chemicals

Palbociclib, ribociclib, palbociclib ²H₈ and ribociclib ²H₆ were obtained from Alsachim (Illkirch,
France). HPLC-grade acetonitrile (ACN) and methanol were purchased from Carlo Erba
Reagents (Val De Reuil, France). Formic acid (FA) (98% pure) was obtained from PanReac
AppliChem ITW Companies (Darmstadt, Germany). Dimethylsulfoxide (DMSO) was from
Carlo Erba Reagents (Val De Reuil, France). Ultrapure water (H₂O) was produced with a MilliQ[®] Simplicity apparatus (Millipore Corp., Burlington, MA, USA).

112 2.2. Control plasma and blood sample collection

113 Control plasma samples (blank samples) were obtained from Nîmes University Hospital Center (UHC) and were stored at -20°C. Patient blood samples were collected in EDTA tubes 114 at the Montpellier Regional Institute of Cancer (ICM, Montpellier, France) and at Nîmes UHC, 115 centrifuged and stored at -80°C till analysis. Patient blood samples were from patients with 116 117 metastatic breast cancer treated with an aromatase inhibitor (letrozole or anastrozole) and 118 CDK4/6 inhibitor (palbociclib or ribociclib) and enrolled in a multicenter prospective clinical 119 trial (ALCINA 2, NCT04025541) initiated at ICM in 2018 to assess the clinical usefulness of 120 various cancer biomarkers. Patients were included after signature of the informed consent. Cohort 1 (palbociclib) recruitment is already ongoing for patients received 125mg oral 121 palbociclib as per therapeutic indication, once per day for 3 weeks followed by one week off. 122 Gold standard of TDM for oral therapy in cancer is to assess the plasma concentration at the 123 124 predose (C_{trough}) at the steady-state (one to two weeks after treatment start depending on elimination half-lives). Blood samples were collected at day 15 (steady-state reached) of the 125 126 first and second treatment cycle before drug administration to estimate plasma exposure (C_{trough}). Cohort 2 (ribociclib) is active but not recruiting yet. Palbociclib plasma concentration 127 128 at the first treatment cycle and at the predose was analyzed for the first twenty patient of 129 cohort 1 (n=18; two patients excluded because blood samples were not collected at C_{trough}). Patients were classified according to their risk of DDI that might lead to inhibition of CYP3A4 130 131 and/or P-glycoprotein. Database search (e.g. DDI predictor[®], Drugs.com[®], Pubmed[®]) allowed the identification of the following drugs that could cause DDI: fluconazole, ivabradine, 132 atorvastatin, amlodipine, losartan and nifedipine [8–12]. 133

134 2.3. Stock and working solutions

Individual stock solutions (1 mg/mL) of palbociclib, ribociclib and internal standards (IS; 135 palbociclib ${}^{2}H_{8}$ and ribociclib ${}^{2}H_{6}$) were prepared in DMSO and stored at -20°C. Mixed 136 palbociclib, ribociclib and IS working solutions were then prepared in ACN/H₂O (50:50, v/v) 137 with 0.1% (v/v) FA by mixing the appropriate volumes of analyte and IS stock solutions. The 138 palbociclib and ribociclib working solution concentrations were 78.12, 156.25, 312.5, 625, 139 140 1250, and 2500 ng/mL. They were used for the preparation of calibration standards and quality control (QC) samples. The final IS concentrations were 2500 ng/mL for all working 141 142 solutions. Independent stock solutions were used for the preparation of the calibration and quality control standards. We also have performed quality control sample testing in two 143 laboratories to ensure reproducibility of the method (data not shown). 144

145 2.4. Calibration standards, quality control, and patient plasma samples

146 To compute the calibration curve over a specific concentration range, calibration standards 147 were prepared by spiking 200 µL of blank plasma with 10 µL of working solution that 148 contained known concentrations (3.9, 7.8, 15.6, 31.5, 62.5, and 125 ng/mL) of palbociclib and ribociclib, respectively. For each calibration standard, the final IS concentration was 125 149 150 ng/mL. To determine the lower limit of quantification (LLOQ), medium, and upper limit of quantification (ULOQ), palbociclib and ribociclib QC samples were prepared at the 151 concentrations of 3.9, 15.6, 50, and 100 ng/mL. All solutions were prepared according to the 152 153 recommendations for bioanalytical method validation [13,14]. Plasma sample (100µl) was mixed with 100 μ L of blank plasma and 10 μ L of the final IS (palbociclib ²H₈) working solution 154 before sample extraction to avoid concentration measurements out of the limit of 155 calibration range. 156

157 2.5. Sample extraction procedure

158 Sample (calibration standards, QC, patient plasma samples) extraction was performed by Solid Phase Extraction (SPE) with Oasis Hydrophilic-Lipophilic Balance (HLB) columns (1cc; 159 160 30gr) (Waters[®]) on a vacuum support. 100 μ L of methanol/H₂O (50:50, v/v) and 1mL of FA 28% (v/v) were added to each sample (final volume: 1.310 mL). SPE columns were first 161 conditioned with 2 mL of methanol and 2 mL of H₂O. Then, samples were loaded on the SPE 162 163 column followed by two rinses (1 mL) with water. Samples were eluted with 1 mL of 164 methanol. Eluted samples were dried and concentrated under a nitrogen stream using a 165 TurboVap[®] device (Air Liquid, France) coupled with a 37°C water bath. Dried extracts were reconstituted with 200 μ L ACN/H₂O (50:50, v/v) and 0.1% (v/v) FA and analyzed (10 μ L) by 166 HPLC-MS/MS. We also compared SPE to liquid-liquid extraction in order to use the most 167 168 cost-effective and reliable extraction technique. SPE has proven to be the technique with the 169 highest repeatability and reproducibility, as well as the best performance (data not shown).

170

171 2.6. HPLC-MS-MS equipment

An Agilent 1100 HPLC instrument linked to a triple quadrupole mass spectrometer (MS/MS)
(API3000, PE Sciex) with a turbo ion spray interface was used for all analyses.
Chromatographic separations were carried out on a Waters Symmetry[®] C18 column (4.6 μm
x 75mm; 3.5 μm). Data were treated with the Analyst 1.5.2 software.

176

177 2.7. HPLC-MS/MS conditions

The column and autosampler temperatures were maintained at 25 °C and 4°C, respectively. Eluent A was 0.1% (v/v) of FA in water and eluent B was ACN with 0.1% (v/v) of FA. Complete separation of palbociclib, ribociclib and IS was obtained using a carefully optimized 22min stepwise gradient with a flow rate of 0.5mL/min: 100% A (0-2 min), 0-50% B (2-8min), 50% B

182	(8-11 min, end of analytical run), 50-100% B (11-14min), 100% B (14-17 min), 100-0% B (17-
183	19 min), and 100% A (19-22 min). The ion source temperature was set to 450°C and the ion
184	spray voltage at 5000 V. The nebulizer, curtain and collision gas pressures were 8, 8, and 4
185	psi, respectively. MS/MS transitions and optimal potential settings were determined for
186	each analyte/IS and are listed in Figure 1.
187	
188	2.8. Method validation
189	The HPLC-MS/MS method was validated according to the FDA and EMA recommendations
190	[13,14].
191	
192	2.9. Statistical analysis
193	The Wilcoxon rank-sum test was used to compare the distribution of quantitative variables
194	(palbociclib plasma exposure and risk of DDI).
195	
196	3. Results
197	3.1 Method development
198	Precursor and product ions were obtained for the investigated analytes and IS with collision
199	energy values of 39 V and 45 V for palbociclib and its IS and for ribociclib and its IS,
200	
	respectively (Figure 1). Precursor ions (Q1, m/z) for palbociclib and its IS was 448 and 456
201	respectively (Figure 1). Precursor ions (Q1, m/z) for palbociclib and its IS was 448 and 456 respectively, and ribociclib and its IS was 435 and 441. Product ions (Q3, m/z) obtained were
201 202	respectively (Figure 1). Precursor ions (Q1, m/z) for palbociclib and its IS was 448 and 456 respectively, and ribociclib and its IS was 435 and 441. Product ions (Q3, m/z) obtained were 379.9, 388, 322 and 322 for palbociclib, its IS, ribociclib and its IS respectively.
201 202 203	respectively (Figure 1). Precursor ions (Q1, m/z) for palbociclib and its IS was 448 and 456 respectively, and ribociclib and its IS was 435 and 441. Product ions (Q3, m/z) obtained were 379.9, 388, 322 and 322 for palbociclib, its IS, ribociclib and its IS respectively. After HPLC gradient optimization, the method specificity was evaluated by replicating
201 202 203 204	respectively (Figure 1). Precursor ions (Q1, m/z) for palbociclib and its IS was 448 and 456 respectively, and ribociclib and its IS was 435 and 441. Product ions (Q3, m/z) obtained were 379.9, 388, 322 and 322 for palbociclib, its IS, ribociclib and its IS respectively. After HPLC gradient optimization, the method specificity was evaluated by replicating analyses using the multiple reaction monitoring (MRM) mode. This mode allows the specific
201 202 203 204 205	respectively (Figure 1). Precursor ions (Q1, m/z) for palbociclib and its IS was 448 and 456 respectively, and ribociclib and its IS was 435 and 441. Product ions (Q3, m/z) obtained were 379.9, 388, 322 and 322 for palbociclib, its IS, ribociclib and its IS respectively. After HPLC gradient optimization, the method specificity was evaluated by replicating analyses using the multiple reaction monitoring (MRM) mode. This mode allows the specific and selective detection, identification and quantification of the components of interest in a
201 202 203 204 205 206	respectively (Figure 1). Precursor ions (Q1, m/z) for palbociclib and its IS was 448 and 456 respectively, and ribociclib and its IS was 435 and 441. Product ions (Q3, m/z) obtained were 379.9, 388, 322 and 322 for palbociclib, its IS, ribociclib and its IS respectively. After HPLC gradient optimization, the method specificity was evaluated by replicating analyses using the multiple reaction monitoring (MRM) mode. This mode allows the specific and selective detection, identification and quantification of the components of interest in a mixture, based on monitoring the precursor-fragment ion pair. Figure 1 shows the

207 chromatogram and retention times obtained for the ribociclib and palbociclib working 208 solutions at 125 ng/mL and their IS. Elution step was maintained up to 22 minutes in order 209 to limit the risk of sample carry-over.

210

211 3.2 Method validation

212 3.2.1 Selectivity

The selectivity of the method (i.e. the ability to differentiate between palbociclib, ribociclib and IS) for endogenous plasma matrix components was evaluated in four different batches of blank plasma. Selectivity was good with no interference observed between analytes and plasma components (Figure 1). Indeed, the signal of the blank matrix was <2% of that obtained for palbociclib and ribociclib at the LLOQ (and <0.2% for the IS).

218

219 3.2.2 Calibration curve

Linearity was assessed using calibration standards at increasing concentrations: 3.9 (LLOQ), 7.8, 15.6, 31.2, 62.5, and 129 (ULOQ) ng/mL of palbociclib and ribociclib, respectively. Five calibration curves were analyzed on different days for each analyte (i.e. palbociclib and ribociclib). All correlation coefficients were >0.998 for palbociclib and ribociclib. All backcalculated concentrations were within 15% of the nominal concentrations (± 20% for the LLOQ). For both analytes, the LLOQ signals were >5 times greater than the signal of the blank sample.

227

3.2.3 Accuracy and precision

Within-run and between-run accuracy and precision were studied using calibration standards with the following concentration levels: 3.9 ng/mL (LLOQ), 15.6 ng/mL (about 3 times the LLOQ), 50 ng/mL (about 40% of the calibration curve), and 100 ng/mL (about 78%

232 of the calibration curve). Accuracy was expressed as the difference (%) between the mean measured concentration and the nominal concentration (bias). Precision was expressed as 233 the coefficient of variation (CV) (%). ANOVA was used to assess the between-run precision. 234 Within-run and between-run accuracy and precision were within the acceptance criteria: ≤ 235 15% for low, medium and high QC and ≤20% for the LLOQ of the QC (Table 1). Accuracy and 236 237 precision measurements were analyzed by pooling repeated results using statistical methods (ANOVA). The standard deviation and the common coefficient correlation were checked 238 239 (Table 1).

240

241 3.2.4. Carry-over

Blank samples were injected after analysis of high-concentration QC samples to evaluate the carry-over. For palbociclib, interference was <5% of the peak area observed at the LLOQ. For ribociclib, interference was <2% of the peak area observed at the LLOQ. For both IS, interference was <0.5% of the IS peak area. These results are fully compliant with the required limits: $\leq 20\%$ of peak areas at the LLOQ for the analytes and $\leq 5\%$ of IS area for IS.

247

248 3.2.5 Matrix effect

The matrix effect was evaluated at the LLOQ and ULOQ. For each analyte, the normalized matrix effect was estimated by dividing the analyte matrix factor (i.e. analyte peak area in plasma divided by the analyte peak area in the water/ACN mixture) by the IS matrix factor (i.e. IS peak area in plasma divided by IS peak area in the water/ACN mixture). For palbociclib and ribociclib, the normalized matrix effect varied between 0.83 and 1.14. The overall CV of the normalized matrix effect was <15%.

255

256 3.2.6 Stability

Plasma samples were stable at ambient temperature for at least 6 hours with observed
variations <5% compared with freshly prepared samples for both palbociclib and ribociclib.
Samples stored at -20°C were stable for at least one month with <15% of difference with the
nominal value.

261

262

263 3.3 Clinical application

The plasma concentration of palbociclib was assessed using our HPLC-MS/MS assay in the first 18 patients treated with palbociclib and aromatase inhibitor in the framework of the ALCINA 2 trial (see Table 2 for their description). The C_{trough} (geometric mean ± standard deviation [min-max]) was 88.58 ng/mL ± 26.4 [46.5 ng/mL – 133 ng/mL] at day 15 of the first cycle of palbociclib treatment, with a CV(%) of 29.8 (Figure 2).

No correlation between plasma concentration and body weight or area was found. DDIlinked pharmacokinetic variabilities, such as drug absorption or metabolism, can modulate palbociclib plasma exposure. Besides palbociclib and aromatase inhibitor treatment, the 18 patients were taking other drugs (mean number: 3.22 per day; min-max: 0-7). Therefore, they were divided in two groups based on the presence (n=7) or not (n=11) of potential DDI (CYP3A4 and P-glycoprotein inhibitors listed in 2.2). Palbociclib C_{trough} at day 15 was significantly different in patients with and without potential DDI (p<0.01) (Figure 2).

276

277

278 **4. Discussion and conclusion**

279

Here, we described a specific, accurate and sensitive HPLC-MS/MS method that we developed and validated for the simultaneous estimation of ribociclib and palbociclib

282 exposure in patient plasma samples. Most efficient extraction and interlaboratory control have allowed, between quality criteria, a useful and effectiveness method in TDM clinical 283 use. In this first study, the method was also used to monitor palbociclib exposure in a real-284 life cohort of 18 patients with locally advanced metastatic breast cancer treated with 285 palbociclib and an aromatase inhibitor. Like for most kinase inhibitors used in oncology, the 286 287 relationship between pharmacokinetics and pharmacodynamics of CDK4/6 inhibitors assessed by TDM could help to improve the treatment efficacy and reduce toxicities. 288 289 However, with the exception of the data from the PALOMA trials or from small cohorts, clinicians do not have much information on palbociclib plasma exposure [7]. Our preliminary 290 analysis in 18 patients showed a mean Ctrough of 88.58 ng/mL, similar to what reported in the 291 292 PALOMA trials. In the PALOMA 1 trial, the geometric mean C_{trough} was 88.5 ng/mL (n=6) [15]. 293 In the PALOMA 2 trial, the mean C_{trough} of palbociclib (%CV) at the steady state was 61 ng/mL (42%), with a mean C_{max} at 116 ng/mL (28%) [16]. In the PALOMA 2 subgroup, ethnicity 294 influenced plasma exposure. Specifically, palbociclib Ctrough was higher in Japanese patients 295 296 (n=27) than in non-Asian patients (n=142) (95.4 ng/mL versus 61.7 ng/mL) [17]. Our cohort included only Caucasian patients treated with palbociclib (125mg per day; full dose). DDI 297 298 mediated by drug metabolizing enzymes and transporters are a major source of 299 pharmacokinetic variability. In our subgroup with potential DDI, interactions between 300 palbociclib and CYP3A4 or P-glycoprotein inhibitors could explain the palbociclib concentration variability (74.15 ng/mL vs 111.26 ng/mL with DDI). Additional studies are 301 302 needed to characterize palbociclib pharmacokinetic variabilities that could explain plasma 303 concentration variations between patients, and their clinical impact. These preliminary data 304 must to be confirmed in both cohorts of the ALCINA 2 study (once enrollment will be

306	according to pharmacokinetic and pharmacogenetic data integrated in a decision algorithm.						
307							
308							
309	Declaration of competing interest:						
310	No competing interests to declare for all authors/provided financial support for the conduct						
311	of the research						
312	Acknowledgments: Benoit Blanchet (Hopital de Cochin, Paris, France) and Laboratoire de						
313	Mesures Physiques (Université de Montpellier, France) for quality control sample testing.						
314	Funding source: This project was supported by INCa-Cancéropôle GSO.						
315							
316	[1] Thill M, Schmidt M. Management of adverse events during cyclin-dependent kinase						
317	4/6 (CDK4/6) inhibitor-based treatment in breast cancer. Ther Adv Med Oncol						
318	2018;10:175883591879332. https://doi.org/10.1177/1758835918793326.						
319	[2] Lucas CJ, Martin JH. Pharmacokinetic-Guided Dosing of New Oral Cancer Agents. J						
320	Clin Pharmacol 2017;57:S78–98. https://doi.org/10.1002/jcph.937.						
321	[3] Widmer N, Bardin C, Chatelut E, Paci A, Beijnen J, Levêque D, et al. Review of						
322	therapeutic drug monitoring of anticancer drugs part two – Targeted therapies. Eur J Cancer						
323	2014;50:2020–36. https://doi.org/10.1016/j.ejca.2014.04.015.						
324	[4] Herviou P, Thivat E, Richard D, Roche L, Dohou J, Pouget M, et al. Therapeutic drug						
325	monitoring and tyrosine kinase inhibitors. Oncol Lett 2016;12:1223–32.						
326	https://doi.org/10.3892/ol.2016.4780.						
327	[5] Martínez-Chávez A, Rosing H, Hillebrand M, Tibben M, Schinkel AH, Beijnen JH.						
328	Development and validation of a bioanalytical method for the quantification of the CDK4/6						
329	inhibitors abemaciclib, palbociclib, and ribociclib in human and mouse matrices using liquid						
330	chromatography-tandem mass spectrometry. Anal Bioanal Chem 2019;411:5331–45.						
331	https://doi.org/10.1007/s00216-019-01932-w.						
332	[6] Janssen JM, de Vries N, Venekamp N, Rosing H, Huitema ADR, Beijnen JH.						
333	Development and validation of a liquid chromatography-tandem mass spectrometry assay						
334	for nine oral anticancer drugs in human plasma. J Pharm Biomed Anal 2019;174:561–6.						
335	https://doi.org/10.1016/j.jpba.2019.06.034.						
	3						

completed) in order to evaluate the interest of individualizing CDK4-6 inhibitor dosage

336[7]Posocco B, Buzzo M, Poetto AS, Orleni M, Gagno S, Zanchetta M, et al. Simultaneous337quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS

method for clinical application. PloS One 2020;15:e0228822.

339 https://doi.org/10.1371/journal.pone.0228822.

340 [8] Tod M, Goutelle S, Bleyzac N, Bourguignon L. A Generic Model for Quantitative

341 Prediction of Interactions Mediated by Efflux Transporters and Cytochromes: Application to

P-Glycoprotein and Cytochrome 3A4. Clin Pharmacokinet 2019;58:503–23.

- 343 https://doi.org/10.1007/s40262-018-0711-0.
- 344 [9] Drugs.com. Drug Interaction Report : Palbociclib information from Drugs.com.
- 345 DrugsCom n.d. https://www.drugs.com/interactions-check.php?drug_list=1717-0,3602-0

346 (accessed March 23, 2020).

347 [10] Holtzman CW, Wiggins BS, Spinler SA. Role of P-glycoprotein in Statin Drug

Interactions. Pharmacother J Hum Pharmacol Drug Ther 2006;26:1601–7.

349 https://doi.org/10.1592/phco.26.11.1601.

350 [11] Wessler JD, Grip LT, Mendell J, Giugliano RP. The P-Glycoprotein Transport System

and Cardiovascular Drugs. J Am Coll Cardiol 2013;61:2495–502.

352 https://doi.org/10.1016/j.jacc.2013.02.058.

353 [12] Bellet M, Ahmad F, Villanueva R, Valdivia C, Palomino-Doza J, Ruiz A, et al. Palbociclib

and ribociclib in breast cancer: consensus workshop on the management of concomitant

355 medication. Ther Adv Med Oncol 2019;11:175883591983386.

- 356 https://doi.org/10.1177/1758835919833867.
- 357 [13] FDA. Bioanalytical Method Validation Guidance for Industry 2018:44.

358 [14] EMA. Guideline on bioanalytical method validation 2011:23.

359 [15] Tamura K, Mukai H, Naito Y, Yonemori K, Kodaira M, Tanabe Y, et al. Phase I study of

360 palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients. Cancer Sci

361 2016;107:755–63. https://doi.org/10.1111/cas.12932.

362 [16] John K. Leighton, Pharmacological review. Division of Hematology Oncology
 363 Toxicology; 2015.

- 364 [17] Mukai H, Shimizu C, Masuda N, Ohtani S, Ohno S, Takahashi M, et al. Palbociclib in
- 365 combination with letrozole in patients with estrogen receptor–positive, human epidermal
- 366 growth factor receptor 2–negative advanced breast cancer: PALOMA-2 subgroup analysis of

Japanese patients. Int J Clin Oncol 2019;24:274-87. https://doi.org/10.1007/s10147-018-367 368 1353-9.

369

370

371 Figure :

Figure. 1. Chemical structures of the analytes (palbociclib and ribociclib) and their IS 372 (palbociclib ${}^{2}H_{8}$ and ribociclib ${}^{2}H_{6}$) with their retention time (RT) and peak intensity. The 373 table specifies the precursor (Q1) and fragment (Q3) ions selected for each compound of 374 interest. The HPLC-MS/MS conditions are described in section 2.6. 375 Figure 2: Palbociclib plasma exposure at day 15 (n=18) in the whole cohort (n=18) and in the 376

two subgroup with (n=7) and without (n=11) potential DDI. Black crosses represent the 377

subpopulation arithmetic mean values and open circles represent individual patient values. 378



386 Figure 2

	Nominal concentration (ng/mL)	Within-run (n=5)		Between - run (3 runs on 3 days)	
Analyte		Accuracy (bias %)	Precision (CV%)	Accuracy (bias %)	Precision (CV%)
Palbociclib	3.9	8.4 - 16.8	3.0	13.7	3.2
	15.6	0.1 - 10.3	4.6	3.0	3.8
	50.0	0.5 - 12.8	4.7	6.0	5.6
	100.0	0.8 -12.7	5.7	4.4	4.6
Ribociclib	3.9	0.3 - 14.7	5.6	10.5	6.1
	15.6	1.6 - 8.7	5.0	2.1	5.9
	50.0	1.0 - 10.0	7.0	2.6	7.2
	100.0	1.7 - 13.8	7.7	6.1	6.1
391					
392					
393					
394					
395					
396	Table 1. Accuracy and precision perfo	ormances for palb	ociclib and ribocicl	ib analysis	
397					
398					

Description of the patients included in the ALCINA cohort 1 (n=18)

Sex (n, %)	Women (18, 100%)
Breast cancer histological type (n, %)	Ductal (16, 89%)
	Lobular (2, 11%)
Age, mean years (min; max)	62.5 (38;78)
Weight, mean kilogram (min; max)	62.6 (50;82)
Body area (mean m²)	1.66
Ethnicity (n, %)	Caucasian (18, 100%)
Aromatase inhibitor (n, %)	Letrozole (17, 95%)
	Anastrozole (1, 5%)
Palbociclib dose (mg) (n, %)	125 (18, 100%)
Mean number of co-administered drugs per patient (min; max)	3.22 (0;7)
Geometric mean (CV) Geometric median (min;max)	88.58 (29.8%) 92.25 (46.5;133)
Plasma palbociclib concentration (ng/mL), subgroup with potential DDI (n	=7)
Geometric mean (CV)	111.26 (17.9%)
Plasma palbociclib concentration (ng/mL), subgroup without potential DD)I (n=11)
Geometric mean (CV)	74.15 (25.8%)
Table 2. Patients' characteristics and plasma palbociclib concentration	n (day 15 of cycle 1 of